Co-delivery of erlotinib and doxorubicin by MoS2 nanosheets for synergetic photothermal chemotherapy of cancer

Efficacy of First-Third generation EGFR inhibitor combined with chemotherapy as first-line treatment for advanced lung adenocarcinoma in a real-world setting

“…Our study examined the e cacy of ge tinib-erlotinib combined with carboplatin and pemetrexed for rst-line treatment of advanced NSCLC with sensitive EGFR mutations.The study met its primary end point (PFS) at the last day of follow-up (June 30, 2021).The PFS results for the ve treatment arms are clearly divided by the performed test.The PFS of the combination group was signi cantly longer than those in the ge tinib-erlotinib alone group and chemotherapy alone group.The results of our study indicate that ge tinib-erlotinib combined with carboplatin and pemetrexed as rst-line therapy provides better survival bene ts than ge tinib-erlotinib alone.Similar results were also achieved in a previous study in which ge tinib plus pemetrexed provided greater PFS than ge tinib alone(15.8 months vs.10.9 months, HR = 0.69) as rst-line therapy for EGFR-mutated NSCLC [22].The results in another prospective single arm clinical trial achieved a median PFS of 18.0 months for EGFR-mutated patients using pemetrexed plus ge tinib [23].The median OS for our combination group was 32.0 months, which is similar to that reported in the FASTACT-2 study,intercalating chemotherapy with erlotinib [24],Han reported the combination group PFS17.5months,OS32.6 month was longer than those in the ge tinib-group IPFS11.9months,OS 25.8 month [25].In another studies are same[26-30], [31].In this setting, the most important question is whether the combination strategy is better than EGFR TKI alone.Somatic mutations of EGFR have been associated…”

Two-dimensional nanocoating-enabled orthopedic implants for bimodal therapeutic applications

“…Antibacterial phototherapy strategy has been a rising antibacterial method relying on the photo-responsive materials to achieve the biofunctions; thus, it can be remotely operated and does not result in drug-fast bacteria. Recently, numerous twodimensional (2D) materials including molybdenum disulfide (MoS 2 ), [22][23][24] tungsten disulfide (WS 2 ), 25,26 graphene oxide (GO), 27,28 black phosphorus, 29,30 and transition metal carbides/carbonitrides/nitrides (MXene) 31,32 have been employed to kill pathogens because of their intrinsic excellent photothermal and photodynamic properties. Among these 2D materials, GO has been demonstrated greater biocompatibility, and it has captured considerable interest in biomedical areas for different purposes, including drug delivery, biomedical implants, tissue engineering, cancer therapy, biosensors, etc.…”

MoS2-based nanocomposites for cancer diagnosis and therapy

“…Time-staggered administration of erlotinib (Er) and DOX can enhance the anticancer effect, but its clinical application is limited due to different administration routes and formulation parameters. Recently, Liu et al [ 327 ] designed a MoS 2 -based nanoplatform to co-deliver Er and DOX. Under NIR irradiation, the MoS 2 -based nanoplatform could simultaneously release Er and DOX, and greatly improve the anti-cancer effect by synergistic treatment of Er and DOX.…”